HC-1119

Phase 3Small molecule

HHinova Pharmaceuticals Inc.

HC-1119 is one of 50 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

COVID-19Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

HC-1119

HHinova Pharmaceuticals Inc.

Phase 3

1 2

Biaxin

AbbVie

Preclinical

2 3

Singulair

AstraZeneca

Preclinical

1 4

Calciferol

Alnylam Pharmaceuticals

Activella

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 7

Nitrostat

VViatris Specialty LLC

Preclinical

1 8

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 9

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

3 10

Piperacillin/tazobactam

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Recruiting·HHinova Pharmaceuticals Inc.·Phase 3·NCT03851640·417 enrolled

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Terminated·HHinova Pharmaceuticals USA, Inc.·Phase 3·NCT03850795·104 enrolled

COVID-191 trial

HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients

Unknown status·AApplied Biology, Inc.·Phase 3·NCT04986176·602 enrolled

Efficacy1 trial

A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.

Completed·HHinova Pharmaceuticals Inc.·Phase 1·NCT03774056·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for HC-1119. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HC-1119 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HC-1119. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hinova Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHinova Pharmaceuticals Inc.

HC-1119

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Cancer2 trials

COVID-191 trial

Efficacy1 trial

References

Drug Info

Quick Facts

Related News